Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions
PainOther Surgical ProceduresImpacted Third Molar ToothCytochrome P450 CYP2C9 Enzyme Deficiency
Interventions
DRUG

Piroxicam

After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Sao Paulo

OTHER

NCT02450487 - Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery | Biotech Hunter | Biotech Hunter